Lisdexamfetamine Dimesylate Capsules, 10 mg, CII, 100-count bottle, Rx only, Manufactured by: OHM Laboratories, New Brunswick, NJ 08901, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 57664-046-88.
Published November 5, 2025 · Recall initiated: October 28, 2025
Summary
FDA records drug Class II recall D-0144-2026, published November 5, 2025 and initiated October 28, 2025. Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC; Status: Ongoing; Reported quantity: N/A; Lot: Lot #: AD42468, Expiry: 2/28/2026; AD48705, Expiry: 4/30/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25®C, 60%RH) for Lisdexamfetamine dimesylate capsules.
What to do
Voluntary: Firm initiated · Letter
Get an email if LISDEXAMFETAMINE DIMESYLATE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- LISDEXAMFETAMINE DIMESYLATE
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Distributor
- U.S Nationwide.
- Lot
- Lot #: AD42468, Expiry: 2/28/2026; AD48705, Expiry: 4/30/2026.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDALisdexamfetamine Dimesylate Capsules, 70 mg, CII, 100-count bottle, Rx only, Manufactured by: OHMNovember 5, 2025
- FDALisdexamfetamine Dimesylate Capsules, 60 mg, CII, 100-count bottle, Rx only, Manufactured by: OHMNovember 5, 2025
- FDALisdexamfetamine Dimesylate Capsules, 50 mg, CII, 100-count bottle, Rx only, Manufactured by: OHMNovember 5, 2025
- FDALisdexamfetamine Dimesylate Capsules, 20 mg, CII, 100-count bottle, Rx only, Manufactured by: OHMNovember 5, 2025
- FDA0.9% SODIUM CHLORIDE Injection, USP, 100 mL, Rx only, ICU Medical, Inc., Lake Forest, Illinois, 60045, USA,November 5, 2025
- FDAEverolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only,November 5, 2025
Questions about this recall
Was Lisdexamfetamine Dimesylate Capsules, 10 mg, CII, 100-count bottle, Rx only, Manufactured by: OHM Laboratories, New Brunswick, NJ 08901, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 57664-046-88. recalled?
Yes. FDA published recall D-0144-2026 on November 5, 2025. Reported hazard: Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25®C, 60%RH) for Lisdexamfetamine dimesylate capsules.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: LISDEXAMFETAMINE DIMESYLATE.